Olympus Corporation (OLYMY) Stock Price & Analysis
Olympus Corporation (OLYMY) — price $12.40 (-1.59%), as of the Oct 2, 2026 trading session; market cap $13.2B. Expected results Nov 6, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Olympus Corporation · OLYMY · Healthcare · Medical - Devices
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.40 | |
| Change on the day | -1.59% | |
| 52-week range | $8.08–$13.73 | |
| Market capitalisation | $13.2B | |
| Price / earnings (trailing) | 27.52 | |
| Shares traded on the day | 200 | |
| Beta (volatility vs the S&P 500) | 0.21 | |
| Dividends per share (last 12 months) | $0.16 | |
| Dividend yield (last 12 months) | 1.29% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Olympus (OLYMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the OLYMY film — every key number, told as a short cinematic story
~2 min · open the film
What is Olympus (OLYMY), and what does it report?
Short answer · as of
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Healthcare / Medical Devices SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 28,138 people and is led by Robert White. In Q1 FY2026 it reported revenue of $1.54B and net income of $123M. The market values it at $13.2B.
What do the latest results show for Olympus (OLYMY)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $1.54B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.51B Aug 7, 2026
- Latest report · revenue estimate
- $1.42B Aug 7, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 7, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 7, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 7, 2026 | $1.51B | $1.42B | $0.1117 | $0.0536 |
| May 12, 2026 | $1.87B | $1.78B | $0.1422 | $0.0485 |
| Feb 13, 2026 | $1.70B | $1.68B | $0.0839 | $0.1490 |
| Nov 7, 2025 | $1.61B | $1.59B | $0.1170 | $0.1352 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $1.54B | $123M | $0.11 (diluted) |
| Q4 FY2025 | $1.91B | $160M | $0.14 (diluted) |
| Q3 FY2025 | $1.68B | $91M | $0.08 (diluted) |
| Q2 FY2025 | $1.57B | $128M | $0.11 (diluted) |
What are the financial strengths and risks for Olympus (OLYMY)?
Short answer
The distress and quality screens read Altman Z 3.17 · Piotroski F 7. Trailing ratios: ROE 10.2% · ROA 5.1% · current ratio 1.36 · earnings yield 3.7% · free-cash-flow yield 3.3%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 27.52 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
What should you watch next at Olympus (OLYMY)?
Short answer · as of
The next earnings report is expected on Nov 6, 2026. The number it tests is the $94.93 EPS analysts carry for it. Analyst estimates on file carry FY2027 revenue $1.07T · EPS 94.93 · 12 analysts.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.07T
- EPS estimate
- $94.93
Measured against a quoted price of $12.40 (as of Oct 2, 2026).
OLYMY Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Olympus more than an endoscope manufacturer?
Beyond gastrointestinal visualization, Olympus supplies therapeutic, respiratory, urological, surgical, gynecological, and ear, nose, and throat products. Software, computer-assisted diagnosis, operating-room integration, reprocessing, and repair broaden the business further.
What is the OLYMY stock price today?
The last price recorded on this page for Olympus Corporation (OLYMY) is $12.40, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does OLYMY pay a dividend?
Yes. Olympus Corporation (OLYMY) shows a trailing 12-month dividend yield of 1.29%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (44 figures)
The 44 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 120 Broadway, 32ND Floor, NEW York, NY, 10271 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "2951, Ishikawa-machi, Hachioji, TY, 192-8507, JP". |
FMP — 32 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.40 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T06:24:51.373Z. | |
px.change | Change on the day | -1.59% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $13.2B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T06:24:49.821Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 6, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.20 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $8.08–$13.73 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 27.52 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 200 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.21 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Devices | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 28,138 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Robert White | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2026 | $1.54B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2026 | $123M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-07.revenue_actual | Revenue · reported — report date 2026-08-07 | $1.51B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.revenue_estimated | Revenue · estimate — report date 2026-08-07 | $1.42B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_actual | EPS · reported — report date 2026-08-07 | $0.1117 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-07.eps_estimated | EPS · estimate — report date 2026-08-07 | $0.0536 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_actual | Revenue · reported — report date 2026-05-12 | $1.87B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_estimated | Revenue · estimate — report date 2026-05-12 | $1.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_actual | EPS · reported — report date 2026-05-12 | $0.1422 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_estimated | EPS · estimate — report date 2026-05-12 | $0.0485 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_actual | Revenue · reported — report date 2026-02-13 | $1.70B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.revenue_estimated | Revenue · estimate — report date 2026-02-13 | $1.68B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_actual | EPS · reported — report date 2026-02-13 | $0.0839 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-13.eps_estimated | EPS · estimate — report date 2026-02-13 | $0.1490 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.revenue_actual | Revenue · reported — report date 2025-11-07 | $1.61B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.revenue_estimated | Revenue · estimate — report date 2025-11-07 | $1.59B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_actual | EPS · reported — report date 2025-11-07 | $0.1170 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_estimated | EPS · estimate — report date 2025-11-07 | $0.1352 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.17 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 10.2% · ROA 5.1% · current ratio 1.36 · earnings yield 3.7% · free-cash-flow yield 3.3% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2027 | $94.93 | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 | |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $1.07T · EPS 94.93 · 12 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 | |
earn.est_revenue | Revenue estimate, FY2027 | $1.07T | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.16 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.29% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-07.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.51B) with the recorded estimate ($1.42B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-07.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1117) with the recorded estimate ($0.0536) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-07. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-07.revenue_actual,earn.history.depth.2026-08-07.revenue_estimated,earn.history.depth.2026-08-07.revenue_actual.comparison,earn.history.depth.2026-08-07.eps_actual.comparison,earn.history.depth.2026-08-07.eps_actual,earn.history.depth.2026-08-07.eps_estimated,earn.history.depth.2026-05-12.revenue_actual,earn.history.depth.2026-05-12.revenue_estimated,earn.history.depth.2026-05-12.eps_actual,earn.history.depth.2026-05-12.eps_estimated,earn.history.depth.2026-02-13.revenue_actual,earn.history.depth.2026-02-13.revenue_estimated,earn.history.depth.2026-02-13.eps_actual,earn.history.depth.2026-02-13.eps_estimated,earn.history.depth.2025-11-07.revenue_actual,earn.history.depth.2025-11-07.revenue_estimated,earn.history.depth.2025-11-07.eps_actual,earn.history.depth.2025-11-07.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The company structures its operations around three primary divisions: Endoscopic Solutions, Therapeutic Solutions, and Other business segments. Its extensive product portfolio includes advanced gastrointestinal endoscopy systems, incorporating video and ultrasound technologies, as well as GI endotherapy tools for treating colorectal conditions, HPB (hepatopancreatobiliary) issues, and hemostasis. Olympus also delivers comprehensive endoscopic ecosystem solutions, which feature intelligent operating software platforms, AI-driven insights, and computer-aided detection and diagnosis functionalities. Furthermore, it provides reprocessing solutions for endoscopes, including reprocessors, chemicals, and related accessories, supported by essential medical services such as repair center operations. The company also supplies respiratory care devices, offering bronchoscopy systems and solutions for lung cancer and chronic obstructive pulmonary disease. Its urology offerings encompass visualization tools, stone management, and treatments for benign prostatic hyperplasia (BPH) and BPH with bladder cancer. Within its surgical segment, Olympus features surgical endoscopy systems, cutting-edge energy devices, surgical microscopes, integrated operating room solutions, rhino-laryngoscopy systems, and instruments tailored for ear, nose, and throat surgeries. Various gastroenterology and gynecology devices further round out its product offerings. Established in 1919, the company was initially known as Olympus Optical Co., Ltd., before officially changing its name to Olympus Corporation in October 2003. Its global headquarters are situated in Hachioji, Japan. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.